135 related articles for article (PubMed ID: 16020405)
1. Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril.
Ko GT; Tsang CC; Chan HC
Adv Ther; 2005; 22(2):155-62. PubMed ID: 16020405
[TBL] [Abstract][Full Text] [Related]
2. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats.
Kalender B; Oztürk M; Tunçdemir M; Uysal O; Dagistanli FK; Yegenaga I; Erek E
Acta Histochem; 2002; 104(2):123-30. PubMed ID: 12086332
[TBL] [Abstract][Full Text] [Related]
3. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
4. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
Estacio RO; Coll JR; Tran ZV; Schrier RW
Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
[TBL] [Abstract][Full Text] [Related]
5. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.
Ravid M; Brosh D; Levi Z; Bar-Dayan Y; Ravid D; Rachmani R
Ann Intern Med; 1998 Jun; 128(12 Pt 1):982-8. PubMed ID: 9625684
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of valsartan versus enalapril in heart failure patients.
Willenheimer R; Helmers C; Pantev E; Rydberg E; Löfdahl P; Gordon A;
Int J Cardiol; 2002 Oct; 85(2-3):261-70. PubMed ID: 12208593
[TBL] [Abstract][Full Text] [Related]
7. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
Katayama K; Nomura S; Ishikawa H; Murata T; Koyabu S; Nakano T
Kidney Int; 2006 Jul; 70(1):151-6. PubMed ID: 16710356
[TBL] [Abstract][Full Text] [Related]
8. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
9. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Ikeda H; Hamamoto Y; Honjo S; Nabe K; Wada Y; Koshiyama H
Diabetes Res Clin Pract; 2009 Jan; 83(1):117-8. PubMed ID: 19062123
[TBL] [Abstract][Full Text] [Related]
10. Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Karalliedde J; Maltese G; Hill B; Viberti G; Gnudi L
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1899-905. PubMed ID: 23929932
[TBL] [Abstract][Full Text] [Related]
11. Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).
; Uzu T; Sawaguchi M; Maegawa H; Kashiwagi A
Hypertens Res; 2008 Jun; 31(6):1171-6. PubMed ID: 18716365
[TBL] [Abstract][Full Text] [Related]
12. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
[TBL] [Abstract][Full Text] [Related]
13. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
Viberti G; Wheeldon NM;
Circulation; 2002 Aug; 106(6):672-8. PubMed ID: 12163426
[TBL] [Abstract][Full Text] [Related]
14. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria.
Ahmad J; Siddiqui MA; Ahmad H
Diabetes Care; 1997 Oct; 20(10):1576-81. PubMed ID: 9314638
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia/reperfusion injury as well as doxorubicin cardiotoxicity.
Bozcali E; Dedeoglu DB; Karpuz V; Suzer O; Karpuz H
Acta Cardiol; 2012 Feb; 67(1):87-96. PubMed ID: 22455094
[TBL] [Abstract][Full Text] [Related]
16. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.
Holwerda NJ; Fogari R; Angeli P; Porcellati C; Hereng C; Oddou-Stock P; Heath R; Bodin F
J Hypertens; 1996 Sep; 14(9):1147-51. PubMed ID: 8986917
[TBL] [Abstract][Full Text] [Related]
17. Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy.
Suzuki K; Souda S; Ikarashi T; Kaneko S; Nakagawa O; Aizawa Y
Diabetes Res Clin Pract; 2002 Sep; 57(3):179-83. PubMed ID: 12126767
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
[TBL] [Abstract][Full Text] [Related]
19. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
20. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
Hollenberg NK; Parving HH; Viberti G; Remuzzi G; Ritter S; Zelenkofske S; Kandra A; Daley WL; Rocha R
J Hypertens; 2007 Sep; 25(9):1921-6. PubMed ID: 17762658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
